UOC
GTHX

UBS O'Connor’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

UBS O'Connor’s Portfolio GTHX Stock Details GTHX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-65,000
Closed -$3.4M – 304
2018
Q3 		$3.4M Buy
+65,000
New +$3.54M 0.08% 139

Other funds holding GTHX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS O'Connor's GTHX Position: Q4 2018 in Review

UBS O'Connor sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q4 2018, closing a stake of 65,000 shares — an estimated $3.4M sold.

UBS O'Connor first reported a position in GTHX in Q3 2018 and held it in 1 quarter. The position peaked at $3.4M in Q3 2018. 93 funds tracked by Wall St. Rank hold GTHX as of Q4 2018.

  • UBS O'Connor reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • UBS O'Connor sold 65,000 G1 Therapeutics, Inc. Common Stock shares in Q4 2018, an estimated $3.4M.
  • UBS O'Connor first reported a position in G1 Therapeutics, Inc. Common Stock in Q3 2018 and held it in 1 quarter.
  • UBS O'Connor's G1 Therapeutics, Inc. Common Stock position peaked at $3.4M in Q3 2018.
  • 93 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q4 2018.

Based on UBS O'Connor's 13F filing for Q4 2018, filed 15 Feb 2019.